News

Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company focused on the commercialisation of its innovative oral iron therapy for iron deficiency, Accrufer®/Feraccru® (ferric maltol), announces that the following documents have now…

CEO, Greg Madison, and CFO, Hans-Peter Rudolf, will be hosting a live online presentation relating to the final results via the Investor Meet Company platform at 16.30 (BST) on Thursday 27 April 2023.

Shield Therapeutics plc announces that Mr. Andy Hurley will be joining Shield’s Executive Team as Chief Commercial Officer, effective from the 10 April 2023.

Shield Therapeutics plc provides the following unaudited trading update for the year ended 31 December 2022, as well as an update on the Company's progress on the implementation of the collaboration with Viatris Inc.

Shield Therapeutics, confirms that, AOP Health International Management AG ("AOP") has requested the conversion of a portion of the convertible shareholder loan facility between the Company and AOP (the "Shareholder Loan") into 31,438,189 ordinary shares…

Shield Therapeutics plc announces that it has conditionally raised total gross proceeds of approximately £2.6 million through the Open Offer which was announced on 13 December 2022.

Shield Therapeutics plc announces that, further to the announcement on 13 December 2022, confirming the successful completion of the Placing and Subscription, a Circular will shortly be published on the Company's website, and will be posted to…

Shield Therapeutics plc is pleased to announce the successful completion of the placing (the "Placing") and the subscription (the “Subscription”) which were announced earlier today.

Shield Therapeutics plc announces that it will provide a live investor presentation on Wednesday 14 December 2022 at 4.30pm (GMT).

Shield Therapeutics plc announces a proposed equity fundraising by way of a subscription (the “Subscription”) and placing (the "Placing") of new ordinary shares to raise approximately £14.7m in aggregate at a price per share of 6 pence (the "Issue…

Shield Therapeutics plc has entered into an exclusive, multi-year agreement with Viatris Inc., a global healthcare company, to cocommercialize Accrufer®

Shield Therapeutics plc announces that the Korean Food and Drug Administration has agreed that a single pharmacokinetic (PK) study is the only additional study requirement to support a New Drug Application (NDA) submission for Accrufer®.

Shield Therapeutics plc announces that US Food and Drug Administration (‘FDA’) has approved the extension of the expiration for Accrufer® (ferric maltol) from 36 months to 48 months.

Shield Therapeutics announces that a pooled analysis from ferric maltol clinical trials will be presented at the American College of Gastroenterology Annual Scientific Meeting (ACG 2022).

Shield Therapeutics plc (LSE: STX), reports its unaudited interim results for the first half of 2022 (H1:2022) and provides a business update.

Shield Therapeutics plc (LSE: STX), announces the launch of its new corporate brand and website to to support strategic vision and accelerated growth ambitions

Shield Therapeutics plc (LSE: STX), will announce its interim results for the six months ended 30 June 2022 on Thursday 8 September 2022.

Shield Therapeutics plc (LSE: STX), has concluded the formal loan documentation (the “Shareholder Loan Agreement”) in relation to the US$10 million loan (the “Shareholder Loan”) agreed between the Company and AOP Health International Management (“AOP”).

Shield Therapeutics plc announces that Health Canada have screened and accepted the Accrufer® New Drug Submission (“NDS”), filed by Shield’s Licensing Partner, KYE Pharmaceuticals Inc. (“KYE”) earlier this year.

Shield Provides a Business Update, its Final Results for the Year Ended 31 December 2021 and announces a financing agreement of US$10 million.

Shield Therapeutics plc announces that the following documents have now been sent to shareholders.

Shield Therapeutics plc will announce its final results for the year ended 31 December 2021 on Thursday 30 June 2022.

Shield Therapeutics plc announces that KYE Pharmaceuticals Inc. has submitted a New Drug Submission (‘NDS’) to Health Canada for the regulatory review and approval of Accrufer®.

Shield Therapeutics plc announces that it will provide a live investor presentation on Thursday 3 March 2022 at 4.30pm (GMT).

Shield Therapeutics is pleased to provide an update on trading for the year ended 31 December 2021, as well as an update on the Company’s progress on the commercialization of its lead product Accrufer®/Feraccru®.

Shield Therapeutics announces it will host a Key Opinion Leader (“KOL”) event for Investors on “Iron Deficiency Treatment Innovation” with a focus on clinical utility of Accrufer®/Feraccru® on Thursday 10 February 2022 at 10am (EST) / 3pm (GMT).

Shield Therapeutics plc announces that Greg Madison, Chief Executive Officer of Shield, is scheduled to present virtually at the H.C. Wainwright BIOCONNECT Virtual Conference on 10 January, 2022.

Shield Therapeutics plc announces that it has entered into an exclusive license agreement for Accrufer® with KYE Pharmaceuticals Inc. in Canada.

Shield Therapeutics plc announces a progress update on payer coverage of Accrufer® in the US.

Shield Therapeutics plc, announces that it has entered into an exclusive license agreement for Accrufer® with KOREA PHARMA CO.,LTD (“Korea Pharma”) in the Republic of Korea (“South Korea” or “Korea”).

Shield Therapeutics plc, announces that Jose A. Menoyo, M.D., is joining Shield’s Senior Executive Team as Vice President and Chief Medical Officer with immediate effect.

Shield Therapeutics plc, announces its unaudited interim results for the six months ended 30 June 2021.

Shield Therapeutics plc, confirms that, in line with prior guidance, it will launch Accrufer® in the US on July 1, 2021.

Shield Therapeutics plc, announces that further to the announcement issued on 28 May 2021, Greg Madison will join the Board with immediate effect and is fulfilling the role of the Group’s Chief Executive Officer.

Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), announces that Greg Madison has been appointed as Chief Executive Officer…

Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), provides an update on its preparations to launch Accrufer® in the US,…

Shield Therapeutics plc, notes the recent publication in the journal Inflammatory Bowel Diseases of positive long-term results from a study comparing the effectiveness of ferric maltol 30 mg bid with intravenous (IV) iron (ferric carboxymaltose given…

Shield Therapeutics plc, announces that trading in the Company’s Ordinary Shares of nominal value of £0.015 each (“Ordinary Shares”) will begin today on the OTCQX Best Market (“OTCQX”) in the United States, under the ticker symbol “SHIEF”.

Shield Therapeutics plc, announces that the following documents have now been sent to shareholders: Annual Report and Accounts for the year ended 31 December 2020, Notice of Annual General Meeting (“AGM”) 2021.

Shield Therapeutics plc, is pleased to announce the appointment of Fabiana Lacerca-Allen and Anders Lundstrom, as Independent Non-Executive Directors of the Company with immediate effect.

Shield Therapeutics plc, announces its preliminary results for the year ended 31 December 2020.

Shield Therapeutics plc, notes that Australia’s Therapeutics Goods Administration has registered Feraccru® in the Australian Register of Therapeutic Goods to treat iron deficiency with or without anemia in adults.

Shield Therapeutics plc, Placing, Subscription and Open Offer of up to 97,279,730 New Shares at 30 pence per share and Notice of General Meeting.

Shield Therapeutics plc, is pleased to announce the successful completion of the placing (the “Placing“), and the subscription (the “Subscription”) which were announced earlier today raising aggregate gross proceeds of up to £25.0 million for the Company…

Shield Therapeutics plc, announces a proposed fundraising by way of a subscription (the “Subscription”) and placing (the “Placing“) to raise up to £25.0 million in aggregate at a price per share of 30.0 pence (the “Issue Price“).

Shield Therapeutics plc, provides a business and unaudited trading update for the year ended 31 December 2020.